血清干扰素-α2升高与幼年型系统性红斑狼疮疾病活动度和复发风险相关
该研究分析222份血清样本,包括28名健康对照、88例幼年型系统性红斑狼疮(jSLE)患者(159份样本)和35例幼年特发性关节炎(JIA)患者,采用单分子阵列(Simoa)检测血清IFN-α2水平。横断面分析显示活动/中间组IFN-α2中位数高于低疾病活动度(LDAS)组和缓解组,且jSLE患者高于JIA患者和健康对照;纵向分析表明高IFN-α2是持续复发的唯一预测因子,并可预测未来6个月复发。
要点
- 活动/中间组IFN-α2中位数3185 fg/ml,高于LDAS组571 fg/ml(P=0.04)和缓解组271 fg/ml(P<0.001)。
- jSLE患者IFN-α2中位数587 fg/ml,高于JIA患者7 fg/ml(P=0.0017)和健康对照(P=0.017)。
- 缓解或LDAS期IFN-α2异常者未来6个月复发时间短于IFN-α2正常者(P=0.022)。
核心结论
- 血清IFN-α2水平与jSLE疾病活动度相关,并可预测持续复发和未来复发。
- 作者认为IFN-α2定量检测可能有助于这些患者的风险分层和疾病监测。
研究设计与样本
- 共分析222份血清样本,包括28名健康对照、88例jSLE患者(159份样本)和35例JIA患者。
- 采用单分子阵列(Simoa)检测IFN-α2水平,横断面比较各组及疾病活动度亚组间中位数水平,纵向采用广义线性混合模型评估生物标志物检测和预测复发的能力。
主要发现
- 活动/中间组IFN-α2中位数3185 fg/ml(IQR 48-13 703),高于LDAS组571 fg/ml(IQR 57-1310 fg/ml,P=0.04)和缓解组271 fg/ml(IQR 3-56,P<0.001)。
- 所有jSLE患者IFN-α2中位数587 fg/ml(IQR 11-2774),高于JIA患者7 fg/ml(IQR 3-236,P=0.0017)和健康对照(P=0.017)。
- 缓解或LDAS期IFN-α2异常者未来6个月复发时间短于IFN-α2正常者(P=0.022)。
- 多变量分析显示高IFN-α2是持续复发的唯一预测因子(P=0.028)。
临床怎么用
- 原文结论指出,IFN-α2定量检测可能支持jSLE患者的风险分层和疾病监测(作者认为)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study investigated serum IFN-α2 as a putative marker of disease activity and predictor of disease flares in juvenile systemic lupus erythematosus (jSLE). METHODS: A total of 222 serum samples were analysed, including 28 healthy controls (HCs), 88 jSLE (159 samples) and 35 juvenile idiopathic arthritis (JIA) patients. IFN-α2 levels were determined using single-molecule array (Simoa). Cross-sectionally, median IFN-α2 levels were compared between patient groups and disease activity state sub-groups. Time to flare was analysed by linear regression. Longitudinally, the ability of the IFN-α2 and other traditional biomarkers (erythrocyte sedimentation rate/ESR, low C3 and anti-dsDNA antibodies) to detect and predict flares was assessed via a generalised linear mixed model. RESULTS: Cross-sectional analysis showed higher median IFN-α2 levels in the active/intermediate group (median 3185 fg/ml, IQR 48-13 703) compared with the LDAS (571 fg/ml, IQR 57-1310 fg/ml, P = 0.04) and remission sub-groups (271 fg/ml, IQR 3-56, P <0.001). IFN-α2 was higher in all JSLE patients (median 587 fg/ml, IQR 11-2774) as compared with JIA patients (median 7 fg/ml, IQR 3-236, P = 0.0017) and HCs (P = 0.017). JSLE patients in remission or LDAS with abnormal IFN-α2 levels had a shorter time to flare over the subsequent six months compared with those with normal IFN-α2 levels (P = 0.022). Longitudinally, multivariable analysis demonstrated high IFN-α2 to be the only predictor of an ongoing flare (P = 0.028). CONCLUSION: Serum IFN-α2 levels associate with disease activity and can predict ongoing and future flares in jSLE. These findings suggest that quantification of IFN-α2 may support risk stratification and disease monitoring in these patients.
引用
- Natoli V, Crow YJ, Hunt DPJ, et al. Elevated serum interferon-α2 associates with activity and flare risk in juvenile-onset systemic lupus erythematosus. Rheumatology (Oxford). 2025. PMID: 39589907. doi:10.1093/rheumatology/keae643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。